[PDF] Top 20 Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
Has 10000 "Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients" found on our website. Below are the top 20 most common "Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients".
Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
... of mutations that were hardly detectable or undetectable (21% of cases) by di- rect ...sequencing. Mutations missed by direct sequencing were all point ...EGFR mutations in exons 18, 19, and 21 using ... See full document
8
Epidermal growth factor receptor mutations in Lebanese non-small cell lung cancer patients
... uncontrollable cell proliferation and survival. These mutations can be found in 10-40% of NSCLC patients (Noriko Gotoh, 2001), mostly in adenocarcinomas, with the higher frequency observed in female ... See full document
7
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non small cell lung cancer (NSCLC) patients harboring liver metastasis
... EGFR: epidermal growth factor receptor; FISH: fluorescence in situ hybridization; HR: hazard ratio; ...NSCLC: non‑small cell lung cancer; OS: overall ... See full document
7
Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors by Transformation to Small Cell Lung Cancer in an EGFR-mutant Patient
... EGFR-mutation patients in autopsy and genotype ...SCLC patients in terms of EGFR mutation, it was detected in only 5 (4%) ...these patients. Both SCLC and adenocar- cinoma subtype harbored EGFR ... See full document
5
Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations
... driver mutations, treatment paradigm for non-small-cell lung cancer (NSCLC) patients has been ...of epidermal growth factor receptor (EGFR) ... See full document
8
Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
... of epidermal growth factor receptor (EGFR-TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients harboring activating ... See full document
9
Non-small cell lung cancer: the era of targeted therapy
... of current molecular targeted therapies for NSCLC, to propose an algorithm for clinical application of presently available treatment strategies, and to identify future directions for this important area of ...of ... See full document
11
<p>Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer</p>
... in cell signaling, but when incorrectly formed, may stimulate the uncontrolled growth of normal ...that mutations in the epidermal growth factor receptor (EGFR) gene are ... See full document
14
Exploratory cohort study and meta-analysis of <em>BIM</em> deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
... to small size of included study patients; (2) they did not consider other proapoptotic Bcl-2 family members such as BAX, BAK, and other BH3-only proteins including BAD and PUMA which might be key play- ers ... See full document
13
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
... al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib ... See full document
10
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
... Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell ... See full document
9
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
... Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and their long-term prognosis remains ...poor. Epidermal growth factor ... See full document
18
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
... The epidermal growth factor receptor (EGFR) is expressed in the majority of non-small-cell lung cancer ...NSCLC patients respond to treatment with the ... See full document
9
<p>Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date</p>
... of lung cancers with onco- genic mutations, achieving notably improved progression-free (PFS) and overall survival (OS) rates compared to reference chemotherapy ...metastatic non-small – ... See full document
16
Key words
... Background. epidermal growth factor receptor (egfR) tyrosine kinase inhibitors (TKI) such as erlotinib and gefitinib are targeted drugs for the kinase domain of ...of non-small ... See full document
5
Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
... Abstract: Epidermal growth factor receptor-tyrosine kinase inhibitors have improved progression-free survival and overall survival in non-small-cell lung ... See full document
7
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
... with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) such as Erlotinib or Gefi- tinib helps to prolong the progression-free survival (PFS) time, increase the response ... See full document
18
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
... in patients with locally advanced or metastatic pancreatic ...to detect a 33% difference in OS and 569 patients were ...521 patients were randomized to erlotinib 100 mg per day or placebo; the ... See full document
10
An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report
... The hypothesis was that these lesions were metastatic, so further studies were ordered. Breast ultrasonography revealed a mass of 2 cm by 3 cm in her left breast, but a subsequent fine-needle biopsy showed benign ... See full document
8
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
... untreated patients from East Asia with advanced NSCLC who were light or ...nonsmokers. Patients were randomly assigned to treatment with carboplatin and paclitaxel or ...261 patients harbouring an ... See full document
11
Related subjects